Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F24%3A00013645" target="_blank" >RIV/00023736:_____/24:00013645 - isvavai.cz</a>
Alternative codes found
RIV/00843989:_____/24:E0110993 RIV/00216224:14110/24:00135728 RIV/00216208:11140/24:10478853 RIV/00216208:11150/24:10478853 and 7 more
Result on the web
<a href="https://doi.org/10.1038/s41375-024-02215-9" target="_blank" >https://doi.org/10.1038/s41375-024-02215-9</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1038/s41375-024-02215-9" target="_blank" >10.1038/s41375-024-02215-9</a>
Alternative languages
Result language
angličtina
Original language name
Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF
Original language description
Tyrosine kinase inhibitor (TKI) therapy discontinuation with the aim of achieving treatment-free remission (TFR) is becoming more frequent, as an increasing number of chronic myeloid leukemia (CML) patients are achieving stable deep molecular response (DMR, i.e. BCR::ABL1 transcript level ≤0.01% on the International Scale), however, many challenges remain unresolved. Among others, a nonnegligible proportion of patients reported fear, anxiety, or depression both during TFR and when they had to reinitiate TKI therapy [2]. Similar negative feelings are frequently mentioned in the context of the decision to not stop TKI treatment, furthermore, a considerable proportion of patients (17–50%) have been reported to be unwilling to attempt TFR. However, little is known about how many truly eligible patients are unwilling to attempt TFR, the reasons for their decision and what factors are associated with their unwillingness to discontinue long-term therapy since the reports mentioned above have substantial limitations. The surveys were often conducted in a limited number of centres, focused on patients who are able to use internet tools, focused on more educated patients who are connected to patient supportive organisations, and usually not specifically focused on patients who fulfilled the criteria for TKI discontinuation.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Leukemia
ISSN
0887-6924
e-ISSN
—
Volume of the periodical
38
Issue of the periodical within the volume
4
Country of publishing house
GB - UNITED KINGDOM
Number of pages
5
Pages from-to
893-897
UT code for WoS article
001183688000001
EID of the result in the Scopus database
2-s2.0-85187412156